Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Promis Neurosciences Inc    PMN   CA74346M1095

PROMIS NEUROSCIENCES INC (PMN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 05:39:59 pm
0.3 CAD   +11.11%
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
0.265(c) 0.27(c) 0.27(c) 0.27(c) 0.3(c) Last
54 956 83 550 149 501 127 450 264 976 Volume
+6.00% +1.89% 0.00% 0.00% +11.11% Change
More quotes
Financials (CAD)
Sales 2018 0,00 M
EBIT 2018 -9,83 M
Net income 2018 -9,83 M
Debt 2018 -
Yield 2018 -
Sales 2019 0,00 M
EBIT 2019 -15,0 M
Net income 2019 -15,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 74 049x
Capi. / Sales2019 74 049x
Capitalization 74,0 M
More Financials
Company
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease... 
Sector
Biotechnology & Medical Research
Calendar
01/28 | 02:30pmPresentation
More about the company
Latest news on PROMIS NEUROSCIENCES INC
01/17PROMIS NEUROSCIENCES : to Participate in NobleCon15 and CanTech Investment Confe..
PR
01/17ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Con..
GL
2018PROMIS NEUROSCIENCES : to Present at Sachs Associates Neuroscience Innovation Fo..
AQ
2018PROMIS NEUROSCIENCES : to Present at Sachs Associates Neuroscience Innovation Fo..
AQ
2018PROMIS NEUROSCIENCES : Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to S..
AQ
2018PROMIS NEUROSCIENCES : Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to S..
AQ
2018PROMIS NEUROSCIENCES : Issues Year-to-Date Update, Highlighting 2018 Accomplishm..
AQ
2018PROMIS NEUROSCIENCES : Issues Year-to-Date Update, Highlighting 2018 Accomplishm..
AQ
2018PROMIS NEUROSCIENCES : Issues Year-to Date Update, Highlighting 2018 Accomplishm..
AQ
2018PROMIS NEUROSCIENCES : Announces Third Quarter 2018 Results
AQ
More news
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Bio Therapeutic Drugs
Chart PROMIS NEUROSCIENCES INC
Duration : Period :
Promis Neurosciences Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 0,50  CAD
Spread / Average Target 67%
EPS Revisions
Managers
NameTitle
Elliot Goldstein President, Chief Executive Officer & Director
Eugene Williams Executive Chairman
Daniel E. Geffken Chief Financial Officer
Neil R. Cashman Director & Chief Scientific Officer
James Kupiec Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PROMIS NEUROSCIENCES INC11.11%56
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS14.97%49 757
REGENERON PHARMACEUTICALS11.75%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300